KMT2A and leukemia: Additionally, a previous study reported that TAFA dose-dependently enhanced NK cell ADCC against MLL-rearranged B-ALL, achieving up to 60% cytolysis against RS4:11 and improving survival of leukemia-bearing NOG mice.